Third Trial For Teva’s Laquinimod Hinges On SPA From FDA

Teva will initiate a third clinical trial testing the oral multiple sclerosis drug laquinimod after finalizing a special protocol assessment with FDA.

Teva Pharmaceuticals Industries Ltd. will initiate a third Phase III study for the oral multiple sclerosis candidate laquinimod within the “next two to three months,” Head of R&D Global Branded Products Lesley Russell said during a presentation at the Citi 2012 Global Healthcare Conference Feb. 27. The company is waiting to finalize a Special Protocol Assessment with FDA before initiating the study because it is hoping to use a different primary endpoint than the one used in the failed Phase III BRAVO study.

The future of the oral MS treatment has been in question since the drug under-performed on efficacy in the Phase...

More from Clinical Trials

More from R&D

Cell/Gene Therapy Cost Recovery Options Could Include Pre-Approval Public ‘Bridge’ Funding

 
• By 

Expanded funding for cost recovery could dovetail with FDA Commissioner Martin Makary’s idea for a “conditional approval” pathway based on a plausible mechanism of action.

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

LDT Final Act? US FDA Will Not Appeal District Court Decision Vacating Final Rule

 

The US FDA ended efforts to regulate lab-developed tests as medical devices for now when it did not appeal a decision from the Eastern District of Texas that tossed out the agency's final rule.